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Abstract
The Amyloid Precursor Protein (APP) undergoes sequential proteolytic cleavages through the action of b- and c-secretase,
which result in the generation of toxic b-amyloid (Ab) peptides and a C-terminal fragment consisting of the intracellular
domain of APP (AICD). Mutations leading to increased APP levels or alterations in APP cleavage cause familial Alzheimer’s
disease (AD). Thus, identification of factors that regulate APP steady state levels and/or APP cleavage by c-secretase is likely
to provide insight into AD pathogenesis. Here, using transgenic flies that act as reporters for endogenous c-secretase
activity and/or APP levels (GAMAREP), and for the APP intracellular domain (AICDREP), we identified mutations in X11L and
ubiquilin (ubqn) as genetic modifiers of APP. Human homologs of both X11L (X11/Mint) and Ubqn (UBQLN1) have been
implicated in AD pathogenesis. In contrast to previous reports, we show that overexpression of X11L or human X11 does not
alter c-secretase cleavage of APP or Notch, another c-secretase substrate. Instead, expression of either X11L or human X11
regulates APP at the level of the AICD, and this activity requires the phosphotyrosine binding (PTB) domain of X11. In
contrast, Ubqn regulates the levels of APP: loss of ubqn function leads to a decrease in the steady state levels of APP, while
increased ubqn expression results in an increase in APP levels. Ubqn physically binds to APP, an interaction that depends on
its ubiquitin-associated (UBA) domain, suggesting that direct physical interactions may underlie Ubqn-dependent
regulation of APP. Together, our studies identify X11L and Ubqn as in vivo regulators of APP. Since increased expression of
X11 attenuates Ab production and/or secretion in APP transgenic mice, but does not act on c-secretase directly, X11 may
represent an attractive therapeutic target for AD.
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Introduction
One of the pathological hallmarks of Alzheimer’s disease (AD) is
the accumulation of amyloid plaques consisting of toxic b-amyloid
(Ab) peptides. These peptides arise from the sequential cleavage of
the Amyloid Precursor Protein (APP), a type I transmembrane
protein, by two proteases known as b- and c-secretase (Fig. 1A).
APP proteolysis by b-secretase generates an APP C-terminal
fragment (CTF) known as C99. Subsequent cleavage of C99 by c-
secretase results in the release of Ab into the lumen and the APP
intracellular domain (AICD) into the cytosol, where it can
contribute to a transcriptional regulatory complex [1]. In addition
to this amyloidogenic pathway, APP can also undergo non-
amyloidogenic processing via sequential cleavage by a- and c-
secretase (Fig. 1A). a-secretase cleaves within the Ab sequence,
thereby precluding the formation of Ab. a-cleavage produces an
APP CTF known as C83, which also serves as a substrate for c-
secretase activity [1].
c-secretase activity resides in a multi-protein complex that
minimally contains Presenilins, Nicastrin, Aph-1 and Pen-2 [2,3].
Mutations in APP, Presenilin 1 and Presenilin 2 cause familial,
early onset AD [4–7]. In addition, the triplication of the APP locus
as well as promoter mutations in APP that increase APP
expression are associated with AD [8,9]. The function of the
AICD may also be crucial for AD pathogenesis, since each time
Ab is generated, AICD is simultaneously released. AICD, in
conjunction with two PTB domain-containing proteins (Fe65 and
Tip60), can enter the nucleus and regulate the transcription of
target genes, including APP itself [10]. In addition, AICD has also
been implicated in other processes including cell signaling,
apoptosis and calcium homeostasis [11–21]. Therefore, identifying
genes that regulate APP steady-state levels, APP cleavage, and the
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AD pathogenesis.
The X11/Mint protein family consists of three mammalian
members: X11a and X11b, which are expressed in neurons, and
X11c which is ubiquitously expressed. All three X11 proteins
contain a phosphotyrosine binding (PTB) domain, followed by two
PSD95/Dlg/ZO-1 (PDZ) domains [22]. Several observations
suggest links between X11 and AD. First, X11a and X11b have
been found in amyloid plaques in post-mortem AD brains [23,24].
Second, increased X11a and X11b expression in mammalian cells
leads to a reduced secretion of extracellular Ab [25–27], while
transgenicmice expressing eitherX11a orX11b areassociated with
reduced levels of Ab [28,29]. Third, X11 proteins physically
interact with AICD via their PTB domains [30,31] and inhibit
AICD-dependent transcription [32]. Fourth, X11a and X11b
overexpression increases APP steady-state levels both in vitro and in
vivo, likely due to altered maturation in the secretory pathway or
endocytic trafficking of APP [25,27,33,34]. Finally, the X11
proteins bind to presenilin via their PDZ domains [35]. Further-
more, X11a and X11b have been reported to modulate c-secretase
in mammalian cells [36]; however, alterations in the levels of C83
and C99 are not observed in transgenic mice overexpressing X11
[29]. These conflicting observations leave it unclear whether X11
overexpression can regulate c2secretase activity.
Figure 1. Schematics depicting sites of APP cleavage and GAMAREP. (A) The sequential actions of either a-secretase or b-secretase, which
cleaves APP in its extracellular domain, and c-secretase, which cleaves APP within its transmembrane domain, generate AICD and C83 or C99,
respectively. a-secretase cleaves APP within the sequence of Ab, thus precluding the generation of Ab. (B) GAMAREP (GMR-C99-Gal4, UAS-grim)
contains two components: First, C99-Gal4, a chimeric protein with an N-terminal cleavable signal sequence, transmembrane and intracellular domain
(yellow bar) and a C-terminal Gal4 (blue circle) is specifically expressed in the eye and is a substrate for c-secretase. Second, Grim (purple bar) is
expressed under the control of a Gal4-dependent promoter (green bar) as a readout. In the presence of endogenous c-secretase activity (scissor), the
unleashed AICD-Gal4 (yellow bar and blue circle fragment) translocates to the nucleus (dashed curve) and binds to the UAS element and activates
(black arrow pointing to the right) Grim expression. This leads to apoptosis in the eye, resulting in flies with small and rough eyes (red ovals depict
relative eye size). (C) In the absence of c-cleavage, Gal4 remains tethered at the membrane and therefore is unable to activate Grim expression. This
results in flies with increased eye size (i.e., suppression of GAMAREP phenotype). (D) When APP (C99) levels are downregulated, fewer substrate
molecules are available (illustrated as one C99 molecule rather than three in B) to activate Grim-dependent apoptosis. This results in larger
(suppressed) eye size. (E) When AICD is retained in the cytoplasm, or its levels or function are reduced (not illustrated here), apoptosis occurs less
efficiently and the eyes remain large. (F) When AICD-Gal4 mediated transcription is inhibited, apoptosis is also reduced, resulting in flies with larger
(suppressed) eyes. In summary, GAMAREP allows the identification of factors that regulate endogenous c-secretase activity (as in C), as well as factors
that regulate APP steady state levels (as in D), and AICD function, stability and/or cytoplasmic retention (as in E and F). (G) The false positive reporter.
Suppression of GAMAREP can also arise from factors that regulate processes other than APP biology, such as mutations modifying GMR- or Gal4-
dependent transcriptional activation, or apoptosis, which we collectively named false positives. To eliminate these factors, we employed a ‘‘false
positive’’ reporter (GMR-Gal4, UAS-apoptotic gene). True modifiers are those that modify they eye phenotypes of GAMAREP, but not those of the
false positive reporter.
doi:10.1371/journal.pone.0002495.g001
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AD. UBQLN1 encodes a protein with ubiquitin-like (UBL) and
ubiquitin-associated (UBA) domains, as well as Sti1 repeats [37],
which are often associated with chaperone activity [38]. Several
studies suggest links between UBQLN1 and AD. First, in post-
mortem AD brains, UBQLN1 is found in neurofibrillary tangles
[37], a pathological hallmark of AD along with amyloid plaques
[1]. Second, the genomic region containing UBQLN1, 9q22, has
been identified as containing one major candidate gene for
conferring a predisposition to late onset AD [39,40]. Some reports
[41,42], but not others [43–46], suggest that genetic variants in the
UBQLN1 gene, including one known as UBQ-8i that deletes one
Sti1 repeat, are associated with increased risk for the more
prevalent late-onset forms of AD. Further evidence that UBQ-8i
has enhanced toxicity comes from studies in Drosophila demon-
strating that expression of human UBQ-8i in flies leads to earlier
onset and more severe eye degeneration than does expression of
wildtype human UBQLN1 [47]. Third, UBQLN1 binds PS1 and
PS2 [37], and the fly homolog of Presenilin binds to both human
and fly Ubiquilin (Ubqn), respectively [47]. Drosophila ubqn
antagonizes presenilin (psn) function in both loss-of-function and
gain-of-function studies during development and adult-onset
neurodegeneration in vivo [47,48]. Finally, in cultured cells,
downregulation of UBQLN1 expression alters APP levels and Ab
secretion by modulating APP trafficking [49]. However, reports of
altered UBQLN1 expression on APP processing are conflicting
[48–50]. Because increases in APP levels and/or altered APP
processing are likely to be important risk factors for AD, it is
crucial to clarify the effect of UBQLN1 on APP in an in vivo
system. Additionally, since both X11 and UBQLN1 have been
implicated as regulators of APP steady state levels and APP
processing, it is crucial to assess the extent to which each molecule
contributes to the myriad regulations of APP-related processes,
and to determine what their net effect is in vivo.
Drosophila melanogaster is a useful model organism for studying
neurodegenerative diseases and AD-related processes [51–54].
Drosophila contains homologs of APP [55] and all four components
of the c-secretase complex [56,57]. Expression of human APP in
Drosophila results in its cleavage by endogenous a- and c-secretase
activities [58,59]. Furthermore, co-expression of human b-
secretase (BACE1) and human APP fully reconstitutes APP b-
cleavage [60]. In addition, Drosophila contains homologs of X11/
Mint family proteins [22,61] and UBQLN1 with evolutionarily
conserved domain architecture [47,48].
We engineered transgenic flies that act as living reporters for c-
secretase activity in the eye [59] (Fig 1B-F). These flies (GMR-
C99-Gal4, UAS-grim), known as gamma-secretase activity and
APP level reporters (hereafter called GAMAREP), express a
chimeric protein which contains a signal sequence, followed by a
fusion of the C99 fragment of APP to the yeast transcription factor
Gal4. This C99-Gal4 protein is expressed specifically in the
developing eye in the presence of a Gal4 responsive element that
drives an apoptosis-inducing gene known as grim [62,63]. In the
presence of endogenous c-secretase activity (Fig. 1B), AICD-Gal4
is liberated from the membrane, migrates to the nucleus and
activates transcription of grim. The resulting apoptosis generates
flies with small and rough eyes [59]. When c-secretase activity is
impaired (Fig. 1C), Gal4 remains tethered to the membrane,
resulting in less apoptosis. Therefore, the size and roughness of the
eye inversely correlates, in a semi-quantitative manner, with the
level of endogenous c-secretase activity (high levels of activity
results in flies with small eyes while low levels are associated with
nearly normal eyes). These flies act as sensitive reporters for
modest changes (two-fold) in the levels of known c-secretase
components [59]. Though originally intended to identify regula-
tors of c-secretase activity [59], the eye phenotypes of GAMAREP
flies are also expected to be sensitive to genetic perturbations that
alter the levels of APP (Fig. 1D), AICD function, and/or the
transcriptional activity of AICD-Gal4 (Fig. 1E, F). To discriminate
factors that regulate transgene expression levels, Gal4-dependent
transcriptional efficiency or apoptosis, we also generated a false
positive reporter (GMR-Gal4, UAS-apoptotic gene) (Fig. 1G).
True modifiers will be identified as factors that modify only
GAMAREP eye phenotypes, and not those of the false positive
reporter. Here we report the identification of X11L and ubqn as
regulators of APP in Drosophila.
Results
Increased expression of X11L suppresses GAMAREP eye
phenotypes
We carried out a genetic screen (to be described in detail
elsewhere) in which GAMAREP flies were crossed with flies
carrying single insertions of the EP P element on the X
chromosome. EP elements carry a Gal4 responsive promoter
pointing outwards from the end of the transposon. Thus, when
inserted near the 59 end of a gene, EP elements can drive nearby
gene overexpression in a Gal4 dependent manner. From this
screen, we identified one suppressor line, which contains an EP
element insertion in the 59 region of the X11L gene (CG5675)
(Fig. 2A). To confirm that the GAMAREP suppression is due to
overexpression of X11L, we showed that eye-specific overexpres-
sion of X11L (GMR-X11L) (Fig. 2E) indeed suppressed the
GAMAREP small eye phenotype (Fig. 2F compared to C). X11L
overexpression was confirmed using anti-X11L antibodies (Sup-
plementary Fig. S1). Importantly, X11L overexpression had no
effect on the small eye phenotypes of flies expressing apoptosis-
inducing genes under the direct control of GMR-Gal4 (false
positive reporters; [59]) (Fig. 2G compared to D), indicating that
X11L acts specifically on C99, not on GAL4 or apoptotic genes.
To demonstrate that the mechanism we uncovered for X11L is
shared by human X11a, we expressed human X11a specifically in
the fly eye (Fig. 2H). Strikingly, expression of human X11a also
suppressed the small eye phenotype of GAMAREP (Fig. 2I), but
not that of the false positive reporter (Fig. 2J). This suggests that
Drosophila X11L and human X11a show functional conservation
and that mechanisms of action discovered in flies are likely to be
relevant to humans.
X11L overexpression regulates APP at the level of AICD
To determine how increased X11L expression regulates APP in
the GAMAREP system, we established assays for APP levels and
cleavage in Drosophila. Full length human APP (APP695) or C99
was myc-tagged at the C-terminus and expressed in the eye. Tissue
lysates were examined by Western blotting with an anti-Myc
antibody to follow the fate of APP (Fig. 3A) or C99 (Fig. 3B). APP-
Myc or C99-Myc was cleaved by endogenous a- and c-secretase in
both systems, yielding an AICD-Myc fragment (c-secretase
cleaved) and C83 (an a-secretase cleaved fragment) (Fig. 3A and
3B). Furthermore, although no endogenous BACE activity has
been definitively demonstrated in Drosophila, expression of human
BACE in the presence of APP resulted in the generation of C99, in
addition to C83 and AICD (Fig. 2C). RNAi-mediated silencing of
any one of the four components of the c-secretase complex, psn,
nct, aph-1 or pen-2, resulted in attenuated AICD generation and an
increase in the levels of CTFs (c-secretase substrates) (Fig. 3A and
3B). In addition, overexpression of a dominant negative form of
X11 and Ubqn as APP Regulators
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D279A which corresponds to human PS1
D257A [59])
resulted in similar effects on APP processing (Fig. 3C and E).
Since human X11a has previously been shown to bind Presenilin
and regulate c-secretase-mediated cleavage in mammalian cells
[35], we asked if Drosophila X11L overexpression suppressed
GAMAREP by inhibiting c-secretase activity. We crossed flies
overexpressing X11L with flies expressing APP-Myc, and their
progeny weresubjectedto Western blot analysis. In contrast to what
was observed for the knockdown of psn, nicastrin (nct), aph-1 or pen-2
function, we did not see any reduction in AICD levels or any CTF
accumulation (Fig. 3C and D). Similarly, flies overexpressing X11L
in the background of C99-Myc expression also failed to show any
evidence of c-secretase inhibition (Fig. 3E). These results suggest
that the predominant effect of X11L overexpression in vivo is not
due to c-secretase inhibition.
With increased expression of X11L (multiple copies of transgenes),
we observed a slight increase in the steady-state levels of APP (data
not shown), which is consistent with reported findings in mammals
[25,27,33,34]. However,full-length APPand its proteolytic fragments
increased largely in proportion. The slight increase in levels of AICD
is likely to be physiologically inconsequential, since elevated levels of
AICD are predicted to enhance the GAMAREP eye phenotype,
whereas we observed a robust suppression.
To explore if X11L overexpression regulates AICD function
independently of c-secretase regulation, we generated transgenic
flies that overexpressed a fusion protein of the AICD and Gal4
specifically in the eye (GMR-AICD-Gal4). Flies carrying both
GMR-AICD-Gal4 and UAS-hid transgenes (Fig. 4A and 4E,
hereafter called the AICDREP) were viable but exhibited an
almost complete absence of eye tissue, due to extensive apoptosis
of the cells in the eye [62–64]. This AICDREP (Fig. 4E) displayed
a much smaller eye size than that of GAMAREP (Fig. 2C),
presumably because in the AICDREP, Gal4 is not tethered to the
membrane as compared to C99-Gal4, and therefore does not
require any liberation by c-secretase. The AICDREP thus serves
as a useful system to identify genes that regulate AICD function in
vivo (Fig. 4B–D). Remarkably, overexpression of X11L in the
presence of AICDREP almost completely restored the eye size to
wildtype (Fig. 4F). This suggests that the major effect of X11L
overexpression is the c-secretase independent inhibition of AICD.
In addition, expression of human X11a suppressed the AICDREP
as effectively as overexpression of X11L (Fig. 4H), indicating
functional conservation between Drosophila and human X11.
Mammalian X11a has been shown to bind to the AICD via its
PTB domain [30,31]. If X11L overexpression exerts its major
effect on AICD, we would expect that expression of a truncated
X11L lacking its PTB domain (X11LDPTB) should no longer be
able to suppress the GAMAREP or AICDREP phenotypes.
Indeed, eye-specific overexpression of X11LDPTB (Fig. 2K) failed
to suppress both GAMAREP and the AICDREP (Fig. 2L and 4G),
further supporting the hypothesis that X11L regulates AICD
function. Importantly, neither overexpression of X11L,
X11LDPTB nor human X11a affected the GMR-Gal4, UAS-
hid)\ eye phenotype (Fig. 4I-L), suggesting that X11 expression
acts specifically on AICD. Furthermore, the expression of X11L or
X11a did not affect AICD steady-state levels (Fig. 4M), suggesting
that X11 may promote cytoplasmic retention of AICD, or inhibit
its ability to regulate transcription.
X11L overexpression does not affect the c-secretase
mediated cleavage of Notch
Our observation that overexpression of fly and human X11 does
not alter c-secretase mediated cleavage of APP stands in contrast
to a previous report [36]. To explore this issue further, we asked
Figure 2. Overexpression of fly X11L or human X11a specifically
suppresses GAMAREP. (A) Genomic map of Drosophila X11L
(CG5675, cytological location 16B7). The P element insertion (triangle),
X11L coding and the untranslated regions (dark and shaded rectangles,
respectively) are illustrated. X11L encodes a protein with a PTB and two
PDZ domains that are conserved in human X11 proteins. (B–M)
Scanning electron micrographs (SEM) of adult fly eyes of various
genotypes. GAMAREP flies exhibit small, rough eyes (C) as compared to
the wildtype (B). Overexpression of X11L (GMR-X11L) shows no external
eye phenotypes (E), but strongly suppresses GAMAREP eye phenotypes
(F). Expression of human X11a (GMR-X11a), which by itself does not
produce any visible eye phenotypes (H), suppresses GAMAREP
phenotypes as effectively as fly X11L overexpression (I). X11L’s ability
to suppress GAMAREP is dependent on its PTB domain, since
overexpression of X11LDPTB (GMR-X11LDPTB) (K) fails to suppress
GAMAREP eye phenotype (L). The ability of X11 to suppress GAMAREP
eye phenotype is specific, since overexpression of X11L, X11DPTB or
human X11 fails to suppress the eye phenotype of the false-positive
reporter (GMR-Gal4, UAS-grim/reaper) (D, G, J and M). The X11LDPTB
transgene expresses a truncated protein as detected by anti-X11L
antibodies [75]. Of note, strong overexpression of X11L (multiple copies
of GMR-X11L or GMR-Gal4, UAS-X11L) can result in a rough eye
phenotype (data not shown), consistent with previous reports [76].
doi:10.1371/journal.pone.0002495.g002
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another substrate of c-secretase. Notch is a transmembrane
receptor that mediates cell-cell communication events in multiple
developmental contexts [65,66]. Following cleavage of its
extracellular domain (the S2 cleavage), Notch requires c-
secretase-mediated cleavage (denoted S3) to release the Notch
intracellular domain (NICD), and activate downstream signaling
events [67]. To analyze Notch processing, a transmembrane
version of Notch representing the S2 cleaved fragment was Myc-
tagged at its C-terminus and specifically expressed in the fly eye.
Silencing of any one of the four c-secretase components led to
decreased c-cleavage of Notch, as demonstrated by decreased
levels of NICD, and an increase in the levels of uncleaved Notch
(Fig. 5A). Overexpression of Psn
D279A also caused reduced levels of
NICD and an accumulation of uncleaved Notch (Fig. 5B). In
contrast, neither X11L overexpression nor expression of human
X11a led to any significant effects on NICD production (Fig. 5B).
To further test the hypothesis that overexpression of X11L does
not affect c-secretase activity, we searched for a genetic
interactions between X11L and psn in vivo. RNAi-mediated
silencing of psn specifically in the eye (GMR-RNAi-psn) resulted in
flies with small, rough eyes (Fig. 5C). This is likely due to impaired
cleavage of Notch since partial loss of Notch function also results in
small, rough eyes [68]. As expected, overexpression of psn partially
suppressed the rough eye phenotype associated with GMR-RNAi-
psn, while expression of Psn
D279A enhanced this phenotype (data
not shown). In contrast, expression of either Drosophila X11L or
human X11 did not result in enhancement of the GMR-RNAi-psn
eye phenotype (Fig. 5D and 5E), suggesting that overexpression of
X11L does not significantly inhibit c-secretase activity in vivo.
ubqn acts to stabilize the steady-state levels of APP
To study ubqn function in Drosophila, we generated two RNAi
constructs targeted to two independent regions of ubqn (the coding
region and the 39-untranslated region, respectively), and used these
transgenic flies to carry out tissue-specific silencing [47]. As
described previously, ubiquitous expression of RNAi-ubqn resulted
in a loss of detectable Ubqn protein [47]. Both ubqn RNAi
Figure 3. X11L overexpression does not alter APP levels or processing. (A–C, E) Western blotting of adult head lysates from various
transgenic flies. (A) When APP-9Myc is expressed, the endogenous a- and c- secretase mediated cleavages generate C83 and AICD, respectively. RNAi
knockdown of any one of the four components of the c-secretase complex results in reduction of AICD levels and an increase in the levels of C83, as
compared with sibling controls. (B) When C99-9Myc is expressed, the endogenous c-cleavage generates AICD. RNAi knockdown of any one of the
four c-secretase components results in a reduction in AICD levels and a simultaneous increase in levels of the CTFs. (C) Co-expression of human BACE
and APP-9Myc generates C83, C99 and AICD. Overexpression of Psn
DN results in a reduction of AICD and an increase in the levels of c-secretase
substrates (C83 and C99). In contrast, expression of neither X11L nor human X11a results in any alteration in the CTF levels. (D) Western blot
quantifications of APP and its fragments suggest that there are no significant differences in the levels of either full length APP or its fragments as
compared to control. Values are normalized to the corresponding tubulin loading controls. Data from X11 overexpression (dark bars) and control
(white bars) are analyzed by paired t-test. (E) When C99-9Myc is expressed, expression of Psn
DN results in a decrease in AICD levels and an increase in
C83 levels, while overexpression of X11L fails to show any changes. Note that panels depicting CTFs are from the same Western blots exposed for
different lengths of time than the corresponding APP panels. For each sample, sibling flies of the appropriate genotype raised under identical
conditions were used as controls, and are shown immediately adjacent to the corresponding experimental sample (linked by a horizontal bar).
doi:10.1371/journal.pone.0002495.g003
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identical phenotypes in all experiments [47]. Using the same
RNAi hairpins, we carried out eye-specific silencing of ubqn
(GMR-RNAi-ubqn); effects confirmed by Western blotting of head
lysates using anti-Ubqn antibodies (Supplementary Fig. S1).
Though silencing of ubqn function did not lead to any overt
developmental phenotypes (Fig. 6C), it strongly suppressed the
GAMAREP phenotype (Fig. 6B compared with 6A). Importantly,
silencing of ubqn did not alter the false positive reporter eye
phenotypes (Fig. 6D compared with 2D), suggesting that the
suppression of GAMAREP was specifically due to an effect on
C99.
We next investigated how ubqn loss-of-function suppressed
GAMAREP. APP-Myc was co-expressed with human BACE in
the eye. Silencing of ubqn resulted in a reduction of steady state
levels of full length APP as well as its proteolytic fragments (C99,
C83 and AICD) in the eye (Fig. 6G). Importantly, the reduction of
full length APP and its cleaved forms occurred largely propor-
Figure 4. X11L overexpression suppresses the AICDREP. (A–D) Schematic illustration of the AICDREP. (A) AICDREP (GMR-AICD-Gal4, UAS-hid)i s
composed of two transgenic components. One expresses a fusion protein (AICD-Gal4) (yellow bar connected to blue circle) specifically in the eye. The
other expresses the apoptotic gene hid (yellow bar) under the control of the UAS promoter (green bar). The AICDREP flies exhibit almost no eye, due
to extensive apoptosis. The AICDREP serves as a useful system to identify genes that regulate AICD levels (B), transcriptional activity (C), as well as
AICD cytoplasmic retention (D) in vivo. False positive modifiers such as factors regulating the expression levels of transgenes, Gal4’s ability to activate
transcription, or apoptosis can be excluded using GMR-Gal4, UAS-hid (I). (E–L) SEMs of adult fly eye of various genotypes. (E) The AICD reporter flies
exhibit an almost total lack of ommatidia. (F) Overexpression of X11L results in a dramatic suppression of the AICDREP and restores the eye to nearly
wildtype. (G) Overexpression of X11DPTB fails to suppress the AICDREP phenotype. (H) Expression of human X11a also demonstrates dramatic rescue
of the AICDREP eye phenotype. (I–L) Overexpression of X11L, X11DPTB or human X11a does not affect the eye phenotype of GMR-Gal4, UAS-hid
transgene. (M) Western Blotting of adult head lysates. Neither X11L overexpression nor X11a expression alters AICD levels. Each experimental and its
relevant control samples are linked by a horizontal line.
doi:10.1371/journal.pone.0002495.g004
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in the overall steady-state levels of APP, not a decrease in the
activity of any particular secretase.
Since silencing of ubqn resulted in a decrease in AICD levels as a
consequence of reduced APP levels, we asked if silencing ubqn
would also affect the AICD reporter eye phenotypes. RNAi-ubqn
flies were crossed to flies overexpressing Myc-tagged AICD.
Indeed, we observed that eye-specific expression of RNAi-ubqn led
to a modest suppression of the AICDREP (Fig. 6F compared with
6E), and a reduction in AICD levels in vivo (Fig. 6H).
To determine if ubqn acts as a dose-dependent regulator of APP
levels, we examined the consequences of ubqn overexpression on
APP levels. Eye-specific overexpression of ubqn (GMR-ubqn) did
not generate any overt eye phenotypes, or suppress the GAMA-
REP eye phenotypes (data not shown). Expression levels of ubqn
overexpression was confirmed by anti-Ubqn antibodies (Supple-
mentary Fig. S1). However, ubqn overexpression (GMR-Gal4,
UAS-ubqn) led to an increase in APP levels (Fig. 6I). As with
silencing of ubqn, ubqn overexpression increased the steady state
levels of the full length and c-secretase cleaved fragments of APP
largely in proportion, suggesting that perturbation of Ubqn levels
does not affect c-cleavage of APP (Fig. 6I). Together, we
concluded that the suppression of the GAMAREP phenotype
caused by loss of ubqn function is most likely the result of a decrease
in APP steady-state levels. While loss of ubqn strongly suppressed
the GAMAREP phenotype, we did not observe a significant
enhancement of GAMAREP upon ubqn overexpression. This is
most likely due to the fact that our GAMAREP reporter is much
less sensitive in detecting enhancers than suppressors. This is based
on multiple screens carried out to identify modifiers of GAMA-
REP, from which we isolated a dozen GAMAREP suppressors but
no enhancers (unpublished observations).
How Ubqn regulates APP levels is unclear, but could involve
direct interactions between these proteins. To explore this
hypothesis, we asked if Ubqn can bind to APP directly. We
mixed purified GST and GST-Ubqn fusion proteins with lysates
from Schneider 2 (S2) cells transfected with Myc-tagged C99.
Indeed, Myc-C99 specifically bound GST-Ubqn, but not GST
alone (Fig. 6J). Interestingly, in addition to native-sized C99, GST-
Ubqn preferentially bound to high molecular weight products,
which are likely polyubiquitinated forms of C99 (Fig. 6J). Deletion
of the UBA domain, but not the UBL domain, significantly
abrogated the interaction between Ubqn and C99 (Fig. 6J),
indicating that the UBA domain is required for this interaction.
Discussion
Here, we report the identification of two APP regulators, X11L
and Ubqn, using a living reporter, GAMAREP. GAMAREP
allows us to effectively identify regulators of c-secretase activity,
APP steady-state levels and/or AICD function. Both the steady-
state levels and the processing of APP have been demonstrated to
be important in the pathogenesis of AD. However, the function of
AICD, a much less studied APP fragment, may also be crucial for
AD pathogenesis, since AICD is generated along with Ab and may
have functions including transcriptional regulation, signaling,
apoptosis and calcium homeostasis. Importantly, when a protein
regulates multiple aspects of APP, either directly or indirectly, the
combination of GAMAREP, AICDREP, and our in vivo cleavage
assays allows us to uncover the relative contributions of these
regulatory inputs. This is of particular relevance in this study since
both X11 and UBQLN1 have been proposed to have multiple
functions affecting myriad pathways in various systems. Therefore,
it is important to determine in vivo which pathways play
predominant roles in events related to AD pathogenesis. Our
data suggest that the predominant role of X11L is to regulate APP
at the level of the AICD by a process requiring its PTB domain,
whereas the major role of Ubqn is to regulate APP levels, likely
through a direct physical interaction with APP that is dependent
on the UBA domain of Ubqn.
As a modifier of AICDREP, X11L does not regulate AICD
levels. Following c-cleavage, AICD is thought to migrate into the
nucleus. It is likely that X11L overexpression causes cytoplasmic
retention of AICD based on the following observations. In
mammalian cultured cells, X11 overexpression can reduce nuclear
localization of the AICD with Tip60 [69]. Moreover, X11 can
shuttle between the nucleus and cytoplasm to regulate AICD
transcriptional targets [70]. Our functional studies using AIC-
DREP suggest that the PTB domain of X11L is essential for X11’s
ability to regulate AICD. Therefore, our hypothesis is that X11L
Figure 5. X11L overexpression does not regulate the effect of c-
secretase activity on Notch. (A–B) Western blotting of adult head
lysates from various transgenic flies expressing the S2-cleaved Notch
fragment (a c-secretase substrate). (A) Eye-specific silencing of any of
the four component of the c-secretase complex results in a reduction of
NICD levels and an increase in the levels of uncleaved Notch. (B)
Overexpression of either X11L or human X11a fails to alter S2-cleaved
Notch levels or NICD levels, in contrast to expression of Psn
DN. (C–E)
SEMs of adult fly eyes of various genotypes. Eye-specific expression of
either Drosophila X11L (D) or human X11a (E) does not modify the eye
phenotype due to eye-specific knockdown of psn (C). Insets show a
close-up view of the ommatidia.
doi:10.1371/journal.pone.0002495.g005
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direct physical interaction between the PTB domain of X11L and
AICD.
We have also showed that, in contrast to prior studies [36],
X11L overexpression does not inhibit c-secretase activity in vivo.
In Drosophila, none of the APP cleavage products, C83, C99 or
AICD, is affected by X11L overexpression. Moreover, X11L
overexpression does not inhibit c-secretase activity in vivo towards
another key substrate, Notch, at the level of cleavage, or at the
level of genetic interaction with psn. In a prior study, King et al
concluded that X11 inhibits c-secretase activity, based largely on
the findings that extracellular Ab levels were decreased upon X11
overexpression [36]. They interpreted this to be due to decreased
Ab production by c-secretase inhibition. However, decreased
extracellular Ab levels could also result from decreased Ab
secretion or increased Ab degradation. In fact, another in vivo
study suggested that although X11 overexpression led to reduced
Ab levels, levels of C83 and C99 (direct c-secretase substrates) did
not increase [29]. Since overexpression of X11 can increase the
steady-state levels of APP, likely by modulating APP trafficking to
certain compartments in the secretory pathway [25,27,33,34], an
alternative interpretation of work by King et al is that X11
overexpression decreases Ab via its modulation of APP trafficking,
rather than by regulating c-secretase cleavage. Therefore, these
prior studies are, in fact, consistent with our data and
interpretation.
Our data also suggest that the predominant function of ubqn is to
regulate APP levels, not c-secretase activity. We have established
that Ubqn can bind to and stabilize APP. In contrast to the
selective reduction of AICD and increase in CTFs seen following
the knockdown of any one of the four c-secretase components,
both ubqn loss-of-function and ubqn overexpression modify the
levels of APP and its cleavage fragments largely in proportion. Our
results are consistent with findings made by Zhang et al and
different from Hiltunen et al; possible reasons for these differences
are discussed in Zhang et al [50].
In this study, we did not observe any alterations in c-secretase
activity on APP in response to the silencing of ubqn or ubqn
overexpression, similar to observations made by others [48–50].
However, we have previously shown that Ubqn binds to Psn and
antagonizes psn function both during development and during
adult-onset eye neurodegeneration in Drosophila [47]. There are
several ways these observations can be reconciled. c-secretase
activity is known to vary depending upon the substrate and the
tissue in which it acts [71]. It is possible that ubqn antagonizes psn
activity such that its effect on c-secretase is more evident on
Figure 6. Ubqn binds to APP via its UBA domain and modulates APP levels. (A–F) SEMs of adult fly eyes of various genotypes. Eye-specific
ubqn knockdown by itself does not show any visible phenotypes (C). However, silencing of ubqn strongly suppresses the GAMAREP phenotypes
(compare B to A). ubqn knockdown does not modify the eye phenotype of the false positive reporter (GMR-Gal4, UAS-grim/reaper) (see Fig. 2D). (D).
Eye-specific silencing of ubqn modestly suppresses the eye phenotype of AICDREP (compare F to E). (G–I) Western blotting of adult head lysates. (G)
Eye-specific silencing of ubqn leads to decreased levels of APP, CTFs and AICD. (H) ubqn knockdown results in decreased AICD-Myc levels. (I) Eye-
specific overexpression of ubqn results in an increase in the levels of APP, the CTFs and AICD. A non-specific band (marked by an asterisk) serves as
the loading control. (J) GST pulldown assay. The input lanes show C99 levels from 0.1 to 2.5% of the S2 cell lysates used for each pulldown. Compared
with control (GST alone), Ubqn and UbqnDUBL, but not UbqnDUBA, binds to C99. In addition, Ubqn and UbqnDUBL show similar binding to C99, as
well as to higher molecular weight products that are likely polyubiquitinated forms of C99.
doi:10.1371/journal.pone.0002495.g006
X11 and Ubqn as APP Regulators
PLoS ONE | www.plosone.org 8 June 2008 | Volume 3 | Issue 6 | e2495substrates other than APP in the eye. As a result, the modification
of the c-cleavage of APP by ubqn, if any, might be below the
detection limits of our assay. Alternatively, it is well established
that in addition to being the catalytic core of the c-secretase
complex, Psn can also function in a c-secretase independent
fashion [72,73]. Therefore, it is possible that ubqn primarily
inhibits c-secretase independent functions of psn, leaving c-
secretase dependent activity largely intact. In either case, the
primary effect of ubqn on APP appears to be the regulation of APP
steady state levels, and not inhibition of the c-cleavage of APP.
Here, using GAMAREP and AICDREP, in conjunction with in
vivo cleavage analysis, we have identified factors that regulate
APP. Further screens using these tools are likely to identify other
proteins which may have implications for AD pathogenesis. Since
increased expression of X11 attenuates Ab production or secretion
in APP transgenic mice [28,29], but does not act on c-secretase
directly (this work), X11 may present an attractive therapeutic
target for AD. Similarly, since reduced Ubqn levels result in a
modest decrease in APP levels, whereas expression of both human
wildtype and the AD variant of UBQLN1 leads to adult onset,
age-dependent eye degeneration in Drosophila [47], UBQLN1 may
also be considered as a possible drug target for AD.
Materials and Methods
Molecular Biology
A microRNA-based technology [74] was used for RNAi
silencing. To silence psn, nct, aph-1 and pen-2, the respective
coding regions were independently targeted. PCR products of
these microRNA precursors were cloned into pGMR. To generate
GMR-X11L and UAS-X11L, the X11L coding sequence was PCR
amplified from the EST clone, LD29081, and subcloned into each
vector. To generate GMR-human-X11a, a clone of X11a (kindly
provided by Declan McLoughlin) was subcloned into the EcoR1
and Not1 sites of pGMR. To generate GMR-X11DPTB, the insert
of UAS-X11LDPTB [75] was subcloned into pGMR vector. To
generate GMR-AICD-Gal4, the nucleotide region encoding the
predicted human AICD fragment was PCR amplified and fused
in-frame, upstream of an S. cerevisiae Gal4 sequence. To make
GMR-ubqn, GMR-RNAi-ubqnCDS and GMR-RNAi-ubqnUTR,
the inserts from UAS-ubqn, UAS-RNAi-ubqnCDS and UAS-RNAi-
ubqnUTR [47] were subcloned into pGMR vector, respectively.
To generate pGMR-APP-9Myc and GMR-AICD-9Myc, coding
sequence of APP695 or AICD was PCR amplified and cloned in-
frame upstream of a 9xMyc sequences that has been previously
subcloned into pGMR vector. C99-9Myc was also generated by
PCR and subcloned to generate pMT-C99-9Myc and GMR-C99-
9Myc, respectively. To make pGEX-UbqnDUBL, a PCR
fragment encoding UbqnDUBL was subcloned into the EcoR1
and Not1 sites of the modified pGEX4T-1 vector. pGEX-Ubqn
and pGEX-UbqnDUBA, were described previously [47]. All cloned
PCR products were confirmed by DNA sequencing.
Drosophila Genetics and Strains
For the X chromosome EP screen, individual lines of females
carrying a single inserted EP element were individually crossed to
GAMAREP males. Progeny carrying one copy of an EP insertion
and one copy of GAMAREP were examined, and their eye size
compared with control flies derived from a cross of w
1118 females
to GAMAREP males. For experiments involving transgenic flies,
multiple independent fly lines were generated (Rainbow Trans-
genic Flies) and tested for each transgene. UAS-BACE flies [60]
were obtained from Rita Reifegerste via Doris Kretzschmar, and
UAS-hid flies [64] were obtained from Bruce Hay. GMR-Psn
D257A
was described previously [59].
Scanning Electron Microscopy
Freshly sacrificed flies were mounted on their side with one eye
upward on white tape using clear nail polish. All flies were placed
on a rotating platform to permit for orientation under vacuum and
were imaged at 1806magnification and 100 psi using a Hitachi
2460N scanning electron microscope. Analysis of eye phenotypes
was performed as described previously [59].
Antibody Generation
A fusion of GST-TEV to Drosophila X11L residues 452–775,
corresponding to a region within the N-terminal domain, with an
intervening TEV protease recognition site, was purified from E.
coli lysates. Glutathione agarose-retained proteins were cleaved by
TEV protease to remove GST, and used to immunize rabbits
(Imgenex).
Lysate Preparation and Western Blotting
Heads from age and sex-matched adults were disrupted in lysis
buffer, complete protease inhibitor cocktail (Roche) using a
sonicator-3000 from MISONIX. Samples were sonicated. Sam-
ples were boiled, centrifuged, and total protein from 4 heads per
genotype was analyzed by Western blotting. Antibodies used were
anti-Myc (Upstate), anti-Ubqn [47], anti-X11L and anti-Tubulin
(Sigma).
S2 Cell Culture and Transfection
S2 cells were grown in Schneider’s Drosophila medium (Invitro-
gen) supplemented with 10% FBS, 50 units/ml penicillin, and
50 mg/ml streptomycin at room temperature. Transfections were
carried out using MaxFect transfection reagent (Molecula).
Typically, 1.5610
6 cells plated in a 12-well dish were transfected
with 0.7 – 1 mg total plasmid DNA plus 5 mL MaxFect reagent.
Metallothionein promoter expression was induced with 0.5 mM
copper sulfate 24 hours after transfection. S2 cell lysates were
prepared by harvesting transfected cells (,5610
6) in 1 mL lysis
buffer, followed by incubation on ice for 10 minutes and
centrifugation (16,0006g, 10 min) to pellet insoluble debris.
GST Pulldown Assay
10 mg GST fusion proteins purified from E. coli lysates were
retained on 15 mL glutathione beads, and mixed with 400 mgS 2
cell lysate in 1mL total volume. Retained proteins were eluted by
boiling in Laemmli sample buffer, and detected by Western
blotting with anti-Myc antibody (Covance) [47].
Supporting Information
Figure S1 The expression levels of X11L and ubqn transgenes.
(A) We have generated polyclonal antibodies against X11L. X11L
overexpression is accomplished using either an eye-specific
promoter (GMR-X11L) or the eye-specific driver using the
UAS-GAL4 system (GMR-Gal4, UAS-X11L). Western blots of
lysates from fly heads overexpressing X11L or lysates from
Schneider 2 cells overexpressing X11L (MT-X11L) reveal a band
of predicted size using anti-X11L antibodies. (B) Western blots of
lysates from fly heads expressing RNAi-ubqn or ubqn using anti-
Ubqn antibodies. Silencing of ubqn significantly reduces Ubqn
levels, while ubqn overexpression increases Ubqn levels. A non-
specific band (*) serves as protein loading control.
Found at: doi:10.1371/journal.pone.0002495.s001 (1.06 MB TIF)
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